Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Nov 14;6(12):e801. doi: 10.1097/HS9.0000000000000801

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PMC Copyright notice

Figure 3. — Overall survival. (A) acalabrutinib vs IdR/BR,^a (B) acalabrutinib vs IdR/BR by del(17p) and/or TP53 mutation status, and (C) acalabrutinib vs IdR/BR by IGHV mutation status. ^aEighty patients (52%) in the IdR/BR arm crossed over to the acalabrutinib arm. ^bBased on stratified Cox proportional-hazards model, stratified by randomization stratification factors as recorded in interactive voice/web response system. ^cBased on stratified log-rank test, stratified by randomization stratification factors as recorded in interactive voice/web response system. ^dBased on unstratified Cox proportional-hazards model. ^eBased on unstratified log-rank test. ^fBased on IXRS data. BR = bendamustine plus rituximab; CI = confidence interval; HR = hazard ratio; IdR = idelalisib plus rituximab; IGHV = immunoglobulin heavy chain variable region genes; IXRS = interactive voice/web response system; mIGHV = mutated IGHV; NR = not reached; OS = overall survival; TP53 = tumor protein p53; TP53m = mutated tumor protein p53; uIGHV = unmutated IGHV.